Skip to main content

Orphan Drug Designation

BayBiotech.NET

Orphan Drug is a special status designated to a drug or biologics to treat a rare disease or condition. In order to obtain this designation, drug or biologics must meet certain criteria.

Orphan designation qualifies the sponsor for the tax credit and marketing incentives as per Orphan Drug Act. In addition, orphan drug is not subject to a prescription drug user fee unless used for other indications.

For application purposes, sponsor shall submit two copies of a completed, dated, and signed request for designation that contains the following:

(1) A statement that the sponsor requests orphan drug designation for a rare disease or condition.

(2) The name and address of the sponsor; the name of the sponsor's primary contact person.

(3) A description of the rare disease or condition for which the drug will be investigated.

(4) A scientific rationale for the use of the drug for the rare disease or condition.

(5) Where the sponsor of an already approved orphan drug seeks orphan drug designation for the subsequent drug for the same rare disease or condition, an explanation of why the proposed variation may be clinically superior to the first drug.

(6) If a drug is under development for only a subset of persons with a particular disease or condition, a justification that the subset is medically plausible.

(7) A summary of the regulatory status and marketing history of the drug in the United States and in foreign countries.

Application must have supportive documents to demonstrate that the disease or condition for which the drug is intended affects fewer than 200,000 people.
More information about Orphan Drug Status and tips for application can be found at:
Designating an Orphan Product: Drugs and Biologics, http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm

Comments

Popular posts from this blog

ISO Management Standards for Medical Devices

Two main ISO standards that have a direct application to Medical Device Industry are ISO 9001 and ISO 13485. While ISO 9001 is for evolving a Quality Management System for an organization, ISO 13485 has a direct application to Medical Device Industry. Although, ISO standards for a company are not a legal requirement, but provide a validation and ease of global marketing of the product.

A Facility Inspection Checklist

BayBiotech.NET Whether you are a Quality Assurance/ Compliance personnel planning to make a visit for a facility inspection, this checklist will help you prepare an inspection report based on the information that might be required to collect about the facility during the inspection. This checklist may help you evolve different forms for the inspection in order to accumulate complete information about the facility: 1.General information (a) name of establishment inspected (b) date of inspection (c) name(s) of the inspector(s) (d) date of last inspection. 2.Type of inspection Comprehensive, concise, follow-up, special, investigative, announced, and unannounced. 3.Licensing (a) licensing of premises (b) person with supervisory role in establishments (c) adherence to licensing provisions. 4. Activities undertaken on premises manufacturing, wholesale, importation, export, retail, hospital, pharmacy, clinic, nursing and maternity homes. 5. Adequacy and suitability of pre...

Current Status of Decentralized Clinical Trials

D2E Catalyst Past pandemic, concept of decentralized clinical trials (DCT) has drawn attention but yet not replaced traditional site-based trials. Currently, they have become a durable part of mainstream clinical operations, mostly in hybrid form. Regulators now clearly recognize decentralized elements such as telehealth visits, home-health visits, local labs, and remote data collection, and the FDA has formal guidance in place for how to run trials using those methods.   As of its current status, concept of DCT has won, but full decentralization has not. Sponsors are using decentralized components where they reduce patient burden or improve recruitment and retention, while keeping site-based procedures for activities that are harder to decentralize, such as complex exams, investigational product handling, or high-risk monitoring.  The evolving field is still constrained by several unresolved problems and recurring issues such as data quality and validation, operational c...